Cadrenal Therapeutics (CVKD) Investor presentation summary

Strategic focus and mission

• Aims to develop novel, differentiated products addressing critical gaps in acute and chronic anticoagulation for rare and high-risk patients.

• Pipeline targets rare indications with high unmet need, including heparin-induced thrombocytopenia (HIT), end-stage kidney disease (ESKD) with atrial fibrillation (AFib), and patients with left ventricular assist devices (LVAD).

• Addresses a $40B anticoagulation market, with pipeline peak annual revenue potential exceeding $3 billion.

Pipeline and product highlights

• VLX-1005: First-in-class, clinical-stage 12-LOX inhibitor for HIT, with Orphan Drug and Fast Track designations; unique mechanism targets immune-mediated platelet activation.

• Tecarfarin: Oral vitamin K antagonist with a distinct metabolic pathway, suitable for ESKD+AFib and LVAD patients; not metabolized by CYP450 and unaffected by renal impairment.

• Frunexian: Acute parenteral Factor XIa inhibitor, phase 2 ready, for use in complex cardiac surgery and continuous renal replacement therapy.

Clinical and preclinical data

• VLX-1005 demonstrated dose-dependent prevention of platelet aggregation and pulmonary embolism in animal models, without increasing bleeding risk.

• Phase 1 studies showed VLX-1005 is well-tolerated, with no serious adverse events or dose-limiting toxicities in over 100 subjects.

• Phase 2 PoC study (ALATHEA) interim analysis complete; primary endpoint is time to platelet count recovery, with secondary endpoint of composite thromboembolic events.